# EDGAR Filing Document

**Accession Number:** 0001565892
**File Stem:** 0001415889-23-003052
**Filing Date:** 2023-2
**Character Count:** 7087
**Document Hash:** 057f688c34a8b59456127ef4233a7a8d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001415889-23-003052.hdr.sgml**: 20230222

**ACCESSION NUMBER**: 0001415889-23-003052

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20230217

**FILED AS OF DATE**: 20230222

**DATE AS OF CHANGE**: 20230222

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Funck, Jr. Robert E.
- **CENTRAL INDEX KEY:** 0001565892

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-02189
- **FILM NUMBER:** 23655251

**MAIL ADDRESS:**
- **STREET 1:** 100 ABBOTT PARK ROAD
- **STREET 2:** D-378, AP6D-2
- **CITY:** ABBOTT PARK
- **STATE:** IL
- **ZIP:** 60064-6092

**FORMER NAME:**
- **FORMER CONFORMED NAME:** Funck Robert E
- **DATE OF NAME CHANGE:** 20130103
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ABBOTT LABORATORIES
- **CENTRAL INDEX KEY:** 0000001800
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 360698440
- **STATE OF INCORPORATION:** IL
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 100 ABBOTT PARK ROAD
- **CITY:** ABBOTT PARK
- **STATE:** IL
- **ZIP:** 60064-3500
- **BUSINESS PHONE:** 2246676100

**MAIL ADDRESS:**
- **STREET 1:** 100 ABBOTT PARK ROAD
- **CITY:** ABBOTT PARK
- **STATE:** IL
- **ZIP:** 60064-3500

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Funck, Jr. Robert E.<br><sub>(Last) (First) (Middle)</sub><br>100 ABBOTT PARK ROAD<br><sub>(Street)</sub><br>ABBOTT PARK, IL 60064<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2023-02-17 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_EXECUTIVE VICE PRESIDENT_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>ABBOTT LABORATORIES [ ABT ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common shares without par value | 2023-02-17 |  | A |  | 24419<sup>(1)</sup> | A | $0 | 231001 | D |  |
| Common shares without par value |  |  |  |  |  |  |  | 10000<sup>(2)</sup> | I | By Trust |
| Common shares without par value |  |  |  |  |  |  |  | 10000<sup>(2)</sup> | I | By Trust |
| Common shares without par value |  |  |  |  |  |  |  | 18405<sup>(3)</sup> | I | Profit Sharing Trust |
| Common shares without par value |  |  |  |  |  |  |  | 500<sup>(4)</sup> | I | By Daughter |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Option (right to buy)<sup>(5)</sup> | $106.24 | 2023-02-17 |  | A |  | 96301 |  | 2024-02-17 | 2033-02-16 | Common Shares | 96301 | $0 | 96301 | D |  |

---

### Footnotes:

(1) These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.

(2) Held in daughter's annual gift trust.  The reporting person disclaims beneficial ownership of all securities held by the trust.

(3) Balance in the Abbott Laboratories Stock Retirement Trust as of February 17, 2023.

(4) The reporting person disclaims beneficial ownership of all securities held by his daughter.

(5) Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 32,100 on February 17, 2024, 32,100 on February 17, 2025, and 32,101 on February 17, 2026.

**Signature:** /s/ Robert E. Funck, Jr. by Jessica H. Paik, Attorney-in-Fact  
**Date:** 2023-02-22

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**